Measuring Silent Disease Progression in Multiple Sclerosis With a Multimodal Approach
Recruiting
Observational Study
Multiple Sclerosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 77 (estimated)
- Sponsor
- Heinrich-Heine University, Duesseldorf · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This observational study wants to examine the disease progression independent of relapses in patients with Multiple Sclerosis (MS) that are treated with monoclonal antibodies. Participants will be clinically examined every 6 months and optionally receive a magnetic resonance imaging (MRI) every 12 months. The investigators will also take blood for blood biomarker tests with each clinical examinati…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of RRMS or PPMS according to the 2017 McDonald criteria
* Current treatment with monoclonal antibodies (including Natalizumab, Ofatumumab, Ocrelizumab) according to SmPC
* EDSS ≤7.0
Exclusion Criteria:
* Patients with an acute MS relapse and/or a history of intrave…
Contacts
Marc Günter Pawlitzki, PD Dr. med.
+49 02118117887
MarcGuenter.Pawlitzki@med.uni-duesseldorf.de
CONTACT